Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Liver Cancer
.
2022 Feb 18;11(2):87-93.
doi: 10.1159/000523702.
eCollection 2022 Apr.
Author
Masatoshi Kudo
1
Affiliation
1
Editor-in-Chief, Liver Cancer, Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
PMID:
35634425
PMCID:
PMC9109076
DOI:
10.1159/000523702
No abstract available
Keywords:
Durvalumab; Hepatocellular carcinoma; Tremelimumab.
Publication types
Editorial